
BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
One third of Spanish pork export certificates blocked since swine fever outbreak, minister says - 2
6 Famous Urban communities for Shopping on the planet - 3
Step by step instructions to Advance the Eco-friendliness of Your Kona SUV - 4
Vote in favor of your Number one Sort of Cap - 5
NASA set to launch Artemis 2 moon mission today, the 1st crewed lunar flight since 1972
Car Investigation: A Survey of \Past the Outside\ Car
Iranian rockets hit Tel Aviv area, injuring six
Chinese astronauts’ return to Earth delayed over fears spaceship damaged by debris
Examination In progress into Abuse of Japanese Government-Supported Advance
Meet Beef the bulldog, who takes slow walks with his 78-year-old friend
It's official: NASA's Artemis 2 moon mission will break humanity's all-time distance record
A definitive Frozen yogurt Standoff: Which Flavor Rules?
The Effect of Online Organizations on Society: Beating the Difficulties
Video Conferencing Instruments for Virtual Gatherings













